Baird analyst Joel Beatty downgraded Neurogene (NASDAQ: NGNE) from Outperform to Neutral with a price target of $24.00 (from $38.00).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE